- Home
- APOG vs PHVS Comparison
APOG vs PHVS Comparison
Compare APOG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APOG
- PHVS
- Stock Information
- Founded
- APOG 1949
- PHVS 2015
- Country
- APOG United States
- PHVS Switzerland
- Employees
- APOG N/A
- PHVS N/A
- Industry
- APOG Auto Parts:O.E.M.
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- APOG Consumer Discretionary
- PHVS Health Care
- Exchange
- APOG Nasdaq
- PHVS Nasdaq
- Market Cap
- APOG 818.5M
- PHVS 980.9M
- IPO Year
- APOG N/A
- PHVS 2021
- Fundamental
- Price
- APOG $42.41
- PHVS $20.32
- Analyst Decision
- APOG Hold
- PHVS Buy
- Analyst Count
- APOG 1
- PHVS 6
- Target Price
- APOG $45.00
- PHVS $37.17
- AVG Volume (30 Days)
- APOG 355.7K
- PHVS 143.2K
- Earning Date
- APOG 06-27-2025
- PHVS 08-13-2025
- Dividend Yield
- APOG 2.45%
- PHVS N/A
- EPS Growth
- APOG N/A
- PHVS N/A
- EPS
- APOG 2.36
- PHVS N/A
- Revenue
- APOG $1,376,100,000.00
- PHVS N/A
- Revenue This Year
- APOG $6.76
- PHVS N/A
- Revenue Next Year
- APOG N/A
- PHVS N/A
- P/E Ratio
- APOG $17.96
- PHVS N/A
- Revenue Growth
- APOG N/A
- PHVS N/A
- 52 Week Low
- APOG $37.53
- PHVS $11.51
- 52 Week High
- APOG $87.93
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- APOG 54.73
- PHVS 51.42
- Support Level
- APOG $42.34
- PHVS $19.95
- Resistance Level
- APOG $43.27
- PHVS $24.41
- Average True Range (ATR)
- APOG 1.03
- PHVS 1.83
- MACD
- APOG -0.07
- PHVS -0.26
- Stochastic Oscillator
- APOG 40.91
- PHVS 34.41
About APOG Apogee Enterprises Inc.
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.